Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Thalidomide in Higher Risk MDS
NCT00704704Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Sep 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in myelodysplastic syndrome (MDS), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Overall Response Rate at 12 months. Status: unknown.
02
Drugs
thalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00704704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704704.